Injury induces endothelial to mesenchymal transition in the mouse corneal endothelium in vivo via FGF2

JeongGoo Lee, Eric Jung, Martin Heur

USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA

**Purpose:** To determine whether the mouse corneal endothelium enters endothelial to mesenchymal transition (EndoMT) following surgical injury in vivo.

**Methods:** The corneal endothelium in anesthetized mice was surgically injured in vivo under direct visualization. The secretion of interleukin-1 beta (IL-1β) and fibroblast growth factor 2 (FGF2) into the aqueous humor was analyzed with western blotting. The expression of FGF2, Snai1, Zebl, Colla1, Colla2, Fnl, Vim, Cdk2, Ccnel, and Cdh1 was analyzed with semiquantitative RT–PCR in the mouse corneal endothelium ex vivo and in vivo. Knockdown of FGF2 was done using siRNA. Col8a2 was used as a corneal endothelial marker, and Keratocan (Kcnc) was used as a stromal marker. β-actin was used as a loading control.

**Results:** Sequential expression of IL-1β and FGF2 was detected in the aqueous humor after surgical injury. FGF2 treatment induced expression of endothelial to mesenchymal transition–related genes including Snai1, and Zebl in the mouse ex vivo corneal endothelium. This led to increased expression of Colla1, Colla2, Fnl, and Vim and suppression of Cdh1 in a time-dependent manner. Expression of FGF2, Snai1, Zebl, Colla1, Colla2, Fnl, Vim, Cdk2, and Ccnel was completely abolished by FGF2 siRNA knockdown in the mouse corneal endothelium ex vivo. Surgical injury induced FGF2 expression in the in vivo mouse corneal endothelium. The injury-dependent expression of FGF2, Snai1, Zebl, Colla1, Colla2, Fnl, Vim, Cdk2, and Ccnel and the suppression of Cdh1 were inhibited by siRNA knockdown of FGF2 in the mouse corneal endothelium in vivo. Moreover, siRNA knockdown of FGF2 inhibited the formation of the injury-dependent retrocorneal membrane in the in vivo mouse corneal endothelium.

**Conclusions:** These findings suggest that after surgical injury, FGF2 induces the expression of EndoMT-related genes Snai1, Zebl, Colla1, Colla2, Fnl, Vim, Cdk2, and Ccnel in the mouse corneal endothelium in vivo, similar to the human corneal endothelium ex vivo.

The cornea endothelium is composed of a hexagonal monolayer of cells and plays a critical role in maintaining corneal transparency by regulating hydration through its pump function. Adult human corneal endothelial cells (CECs) are arrested at the G1 phase of the cell cycle throughout their life span [1,2]. Because of the cell cycle arrest, the loss of corneal endothelial cells leads to enlargement and spreading of existing endothelial cells. This, in turn, leads to a progressive decline in the cell density, and a decline below approximately 500 cells/mm² leads to decreased corneal transparency and a resultant loss in vision. Vision loss from endothelial dysfunction is a common indication for corneal transplantation. Although adult human CECs are arrested in the cell cycle, severe injury to the corneal endothelium can force the CECs to enter endothelial to mesenchymal transition (EndoMT). Endothelial to mesenchymal transition is a process in which epithelial or endothelial cells undergo a change in cell morphology to a spindle shape and show increased migratory and proliferative capacity. They secrete fibrillar extracellular matrix leading to the formation of a retrocorneal membrane (RCM) [3-5]. Experimental models of RCM formation showed that activated polymorphonuclear leucocytes (PMNs) induce morphological alteration of CECs to spindle-shaped cells [6] and induce expression of type I collagen leading to anterior segment fibrosis [7,8].

Several soluble factors, such as interleukin-1 beta (IL-1β), have been reported to have important roles in cell proliferation and wound healing [6,9-11]. IL-1β modulates inflammation through induction of secondary cytokines such as fibroblast growth factor 2 (FGF2) [12-16]. Corneal endothelial cells produce all isoforms of FGF2 in response to IL-1β stimulation [17-19]. Among the FGF2 isoforms induced by IL-1β, the secreted 18-KDa isoform regulates many components of endothelial to mesenchymal transition in CECs [20-22]. In CECs, FGF2 promotes cell proliferation through degradation of p27 [23,24], enhanced migration via coordinated regulation of CDC42 and RHOA [25], and upregulation of collagen type I expression [26]. Moreover, FGF2 induces a change in CEC morphology to a spindle shape along with loss of contact inhibition through regulation of RhoGTPases [25,27].

Correspondence to: Martin Heur, USC Roski Eye Institute, 1450 San Pablo St., Rm 4802 Los Angeles, CA 90033; email: heur@usc.edu
The endothelial to mesenchymal transition consists of a change in the cell phenotype characterized by loss of cell polarity and adhesion, and reorganization of the cytoskeleton [28,29]. Downregulation of the homotypic junctional protein E-cadherin has also been shown to occur as cells enter endothelial to mesenchymal transition [30]. E-cadherin downregulation is mediated through transcriptional inhibition by SNAI (SNAI1 and SNAI2) and ZEB (ZEB1 and ZEB2) families of transcription factors [31-33]. Moreover, SNAI and ZEB transcription factors also upregulate expression of vimentin, fibronectin, and a1 (COL1A1) and a2 (COL1A2) chains of collagen type I, a major component of RCM, as CECs enter endothelial to mesenchymal transition [28,31,34-38]. We have also reported previously that FGF2 upregulates expression of SNAI1, which, in turn, leads to increased expression of Cdk2 and ZEB1, followed by induction of proliferation and type I collagen expression in human CECs [36]. Moreover, ZEB1 plays a central role in mediating fibrosis in endothelial to mesenchymal transition in human corneal endothelium ex vivo [36]. Although the downstream effects of IL-1β and FGF2 have been studied extensively in the human corneal endothelium in vitro and ex vivo, regulation of endothelial to mesenchymal transition in the corneal endothelium in vivo has not been investigated. Investigating CECs in the laboratory is difficult from a technical standpoint because their behavior is dependent on their environment; that is, they behave differently in vitro versus ex vivo versus in vivo, and the lack of a suitable in vivo model. In the present study, we present evidence that following surgical injury of the corneal endothelium in vitro and ex vivo, regulation of endothelial to mesenchymal transition markers Snail1 and Zeb1, which, in turn, leads to upregulation of fibrosis- and proliferation-related genes in the mouse corneal endothelium in vivo, much like in the human corneal endothelium ex vivo. The results validate siRNA knockdown in vivo in the mouse, respectively, and the colonies used in this study were bred in-house. Mice between ages of 12 and 14 weeks were used for all experiments. Contralateral uninjured eyes were used as controls in in vivo studies. Mice were anesthetized with an intraperitoneal injection of ketamine (60–70 mg/kg) and xylazine (5–10 mg/kg), and they were euthanized with cervical dislocation.

Reagents: Mouse FGF2 was purchased from Cell Signaling Technology (Danvers, MA). IL-1β and rhodamine-conjugated secondary antibody were obtained from Sigma-Aldrich (St. Louis, MO). Anti–ZO1 antibody (61–7300) was purchased from Invitrogen (Carlsbad, CA). Anti-FGF2 antibody (610,072) was purchased from BD Transduction Laboratories (San Jose, CA). Anti-IL-1β antibody (AF-401-NA) was obtained from R&D systems (Minneapolis, MN). 4′,6-Diamidino-2-phenylindole (DAPI) was purchased from Vector Laboratories (Burlingame, CA).

Ex vivo manipulation of mouse corneas: Mouse corneas were excised from enucleated eyes, and the whole corneas were placed endothelial side up in individual wells of a 96-well tissue culture plate. Opti-MEM (Invitrogen-Gibco, Grand Island, NY) was used for organ cultures. The corneas were treated with IL-1β or FGF2 for 7 days during culturing. Following organ culture, the endothelium-Descemet’s membrane complex was carefully stripped and processed for semiquantitative reverse transcription PCR (RT-PCR).

Semi quantitative RT–PCR: Total RNA extraction from the mouse corneal endothelium was performed as previously described [36] with a slight modification. Briefly, cDNA was synthesized with 1 µg of RNA by using iScript reverse transcriptase (Bio-Rad, Hercules, CA) and oligo(dT) primers. Reverse transcription was performed at 42 °C for 90 min. Then, PCR was performed using the first strand cDNA equivalent to 0.05 µg of starting RNA from each sample as the template. The specific primers used are shown in Table 1. The standard PCR conditions were as follows: 5 min at 94 °C, followed by 30 s at 94 °C, 45 s at 53 °C, 30 s at 72 °C, and a final extension for 4 min at 72 °C. The PCR cycles were optimized to ensure that the product intensity fell within the linear phase of amplification, and the annealing temperature was optimized for each primer. β-actin transcript was used as the internal loading control. The amplified products were separated on a 1.5% agarose gel with electrophoresis and visualized with Gel-Red staining, and the band intensity was analyzed using the Image Lab program from Bio-Rad. All PCR products were verified with DNA sequencing.

Gene knockdown with siRNA: The Accell SMARTpool system (Dharmacon, Pittsburgh, PA) was used for siRNA knockdown as previously reported [36,39]. The mouse
Corneal endothelium was transfected on a 96-well plate with 1.5 μM Accell SMARTpool of siRNA targeting FGF2 in Accell delivery medium according to the manufacturer’s instructions. Seventy-two hours after transfection, based on our experience with human ex vivo CEs [36], the medium was changed to medium containing IL-1β. Ten days after the addition of IL-1β, another transfection with 1.5 μM Accell SMARTpool of siRNA targeting FGF2 was performed, and the corneas were cultured for 4 additional days in the presence of IL-1β. The efficacy of FGF2 siRNA was verified with FGF2 RT–PCR. The Accell non-targeting siRNA pool (Dharmacon) was used as a negative control, and transfection efficiency was confirmed with Accell Red Cyclophilin B Control siRNA (Dharmacon).

**Surgical injury of corneal endothelium and siRNA knockdown in vivo:** Mice were anesthetized with an intraperitoneal injection of ketamine and xylazine. A paracentesis was made using a 30-gauge needle at the edge of the right cornea, and a bent-30-gauge needle was introduced into the anterior chamber through the paracentesis to scrape the endothelium. All procedures were performed under direct visualization using an operating microscope, and care was taken not to injure the lens. For siRNA knockdown in vivo, 3 μl of aqueous humor was aspirated, and then 3 μl of 1.5 μM Accell SMARTpool (Dharmacon, Pittsburgh, PA) of FGF2 siRNA or non-targeting siRNA in Accell delivery medium was injected into the anterior chamber 24 h before surgical injury. The uninjected and uninjured contralateral eye was used as the control. Mice were euthanized by intraperitoneal injection of ketamine (60–70 mg/kg) – xylazine (5–10 mg/kg) mixture followed by cervical dislocation, and their eyes were enucleated. Control and injured corneas were excised from the enucleated eyes and processed for RT–PCR and immunofluorescence imaging.

**Detection of aqueous proteins and histopathology:** Mice were anesthetized by intraperitoneal injection of ketamine

---

**Table 1. DNA sequence of the forward and reverse primers.**

| Gene       | Primers (5’-3’)                        |
|------------|----------------------------------------|
| β-actin    | F: GCAGGAGTACGATGAGTCCGG               |
|            | R: CTTTGGGGGATTTGCTCCA                 |
| Col8a2     | F: TGAGGGCCCTAGTCTCTTCCC               |
|            | R: ACAGCTCAAATCCACAGACGT               |
| Col1a1     | F: GGAAGCTTGGTCTCTTGCTTT              |
|            | R: CCCCAGTCCACAGGATT                  |
| Col1a2     | F: CGGTCTTGGCATTCCTGACCT               |
|            | R: ACAACAGGTGTCAGGGTTTA                |
| Snail      | F: CAGGACTCTCTCCAGCCTTG                |
|            | R: CCTGCTGAGCCTTACGTTAC               |
| Zebl       | F: AGAGAGCTGAAAGCTCTGG                |
|            | R: ACTGCAGGGCTTAAAGACATA              |
| Cdh1       | F: GTTTCGGCTATGTGTCTGGG               |
|            | R: GGGATAGGTCTTCAACGCTGT              |
| Fibronectin| F: TAATCTTTCCGCCCCACCCCT              |
|            | R: CAGAGGTGCTGCTGGTGACTTT             |
| Vimentin   | F: CCTCTGATGACACCACACTCA               |
|            | R: CGCTTTGGGGTGGTGTTG                 |
| FGF2       | F: TGCTGTCTCTGTGATGTG                 |
|            | R: GCCCAGTCTTCTGACGCAA                |
| Keratocan  | F: AACTGAGCTACCTGCGTCTGG              |
|            | R: AACTAATACAGGCTGACCCCCT             |
| Ccne1      | F: CCTGCAGAATGCTGTCTAT                |
|            | R: CATCCCACATTCTGCTACA                |
| Cdk2 (NOD) | F: GTGGTCGTAGCTGACCCCTGG              |
|            | R: TGAGGCCGAACGCTAAACTA               |
| Cdk2 (C57) | F: GTGGTCGTAGCTGACCCCTGG              |
|            | R: CCACGGAGTGTCGGCGGTT                |
(60–70 mg/kg) – xylazine (5–10 mg/kg) mixture 24 and 30 h following surgical injury, and aqueous humor was collected using a 36-gauge needle affixed to a 10 µl Hamilton syringe through the paracentesis under direct visualization using an operating microscope. Two to three microliters of 3 µl aqueous humor was aspirated from the uninjured and injured eyes. A protease inhibitor cocktail (Cell Signaling Technology) was added immediately to prevent degradation of the proteins. The total protein concentration in the aqueous humor samples was measured with the Bradford protein assay kit (Bio-Rad) on the day of sample collection. The samples were placed on ice until testing and were analyzed with immunoblotting. Fifteen percent polyacrylamide gel was used for detection of FGF2 [17] and IL-1β [40] in aqueous humor.

**Histology:** Whole eyeballs were fixed in 10% paraformaldehyde in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na$_2$HPO$_4$, 2 mM KH$_2$PO$_4$, pH 7.4) at room temperature overnight. The eyes were dehydrated in a series of ethanol baths, treated with xylol, and then embedded in paraffin with the axis of the wound perpendicular to the bottom of the mold. Corneal cross sections were cut at 5 µm thickness, and then deparaffinized with a series of xylol and alcohol rinses. The sections were rinsed in PBS three times for 5 min each, followed by a final rinse with distilled water. The sections were then stained with hematoxylin and eosin (H&E).

**Statistical analysis:** Means and standard error of the means (SEM) were calculated for each data set. One-way ANOVA (ANOVA) was performed to compare the means within the groups, and post hoc Tukey’s honestly significant difference intervals at 0.05 and 0.01 levels of confidence were calculated for pairwise comparisons among the means in each group.

## RESULTS

**Injury induces IL-1β and FGF2 production in the mouse corneal endothelium in vivo:** We previously reported that transcorneal freezing induces sequential expression of IL-1β and FGF2 in the rabbit corneal endothelium in vivo [6]. To test the roles of IL-1β and FGF2 in corneal wound healing in the NOD mice, the corneal endothelium was surgically injured in the mouse in vivo. Hematoxylin and eosin staining showed a well-organized monolayer of normal corneal endothelial cells in the uninjured control cornea (Figure 1A). Thickened and disorganized Descemet’s membrane with abnormal corneal endothelial cells was observed in the cornea 4 weeks after the surgical injury (Figure 1A). IL-1β and FGF2 could be detected by immunoblotting in the aqueous humor of the mouse following the surgical injury. The 17-KDa active form of IL-1β was detected in the aqueous humor 24 h after the surgical injury, but the amount was dramatically reduced at 30 h after injury. No IL-1β was detected in the aqueous humor of the control uninjured eyes (Figure 1B). The 18-KDa isofrom of FGF2 was detected in the aqueous humor 30 h after the surgical injury but not in the aqueous humor of the uninjured control eyes (Figure 1C). Interestingly, the amount of FGF2 was statistically significantly lower at 24 h than at 30 h after injury. These results are consistent with our previous findings that only the 18-KDa FGF2 is secreted into the extracellular space among the isoforms of FGF2 [41] and the secretion of IL-1β preceeds expression of FGF2 [6,7,17].

**FGF2 induces endothelial to mesenchymal transition in the mouse corneal endothelium ex vivo:** The role of FGF2 in endothelial to mesenchymal transition of the human corneal endothelium ex vivo [36] led us to investigate whether FGF2 plays a similar role in the mouse corneal endothelium. Similar to the human corneal endothelium, FGF2 stimulation led to overexpression of Snail and Zeb1, starting at 2 days and rising steadily until 7 days post FGF2 treatment, in the mouse corneal endothelium ex vivo (Figure 2A). Time-dependent activation of Coll1a1, Colla2, fibronectin (Fn1), and vimentin (Vim) and suppression of E-cadherin (Cdhh1) expression were also observed in response to FGF2 in the mouse corneal endothelium ex vivo (Figure 2B). Next, we investigated the role of the FGF2 in CEC proliferation in the mouse corneal endothelium ex vivo. FGF2 has been shown to induce proliferation following endothelial injury in the human corneal endothelium ex vivo [36]. FGF2 induced expression of Cdk2 and Cyclin El (Ccnel) in a time-dependent manner in the mouse corneal endothelium ex vivo (Figure 2C). The expression of α2 chain of collagen type VIII (Col8a2), a corneal endothelial marker, and β-actin (Actb), the loading control, were not altered by FGF2 (Figure 2D).

To determine whether the strain of the mouse has an impact, we repeated the RT–PCR experiments in the C57BL/6 strain of mice. Similar to the NOD mice, FGF2 increased the expression of Snail and Zeb1 in the C57BL/6 mouse corneal endothelium ex vivo (Figure 2E). Moreover, expression of Coll1a1, Colla2, Fnn1, and Vim was also increased, while expression of Cdhh1 was decreased by in the C57BL/6 mouse corneal endothelium ex vivo (Figure 2F). FGF2 also induced Cdk2 and Ccnel (Figure 2G), while there were no changes in the Col8a2 and Actb expression in the C57BL/6 mouse corneal endothelium ex vivo. We used NOD mice for all the subsequent experiments because of the easier visualization of the anterior segment anatomy in the NOD mice.

**IL-1β induces endothelial to mesenchymal transition through FGF2 in the mouse corneal endothelium ex vivo:** It has been previously reported that IL-1β activates endothelial to mesenchymal transition through FGF2 in the rabbit [6,40] and human...
corneal endothelium. To investigate the role of IL-1β in endothelial to mesenchymal transition in the mouse ex vivo corneal endothelium, we used siRNA-mediated knockdown of FGF2. IL-1β stimulation in the mouse corneal endothelium ex vivo dramatically induced FGF2 mRNA. FGF2 siRNA transfection in the mouse corneal endothelium ex vivo led to knockdown of the IL-1β-dependent expression of FGF2 mRNA (Figure 3A). FGF2 knockdown was not observed with non-targeting control siRNA transfection (Figure 3A).

The endothelial to mesenchymal transition–related transcription factors Snai1 and Zeb1 were highly induced by the IL-1β treatment, and these IL-1β-dependent inductions were inhibited with FGF2 siRNA knockdown in the mouse corneal endothelium ex vivo (Figure 3A). FGF2 knockdown also led to inhibition of the IL-1β-dependent expression of Colla1, Colla2, fibronectin (Fn1), and vimentin (Vim) and inhibited the IL-1β-dependent suppression of E-cadherin (Cdh1) expression in the mouse corneal endothelium ex vivo (Figure 3B). IL-1β also activated expression of Cdk2 and cyclin E1 (Ccen1; Figure 3C), but this was abrogated by FGF2 knockdown. Non-targeting control siRNA transfection did not affect the expression of Col8a2 and Actb (Figure 3D).

These results suggest that FGF2 acts downstream of IL-1β during endothelial to mesenchymal transition in the mouse corneal endothelium ex vivo.

Injury induces endothelial to mesenchymal transition through FGF2 in the mouse corneal endothelium in vivo: We next investigated the role of FGF2 in regulation of endothelial to mesenchymal transition in the mouse corneal endothelium in vivo by performing a surgical injury with FGF2 siRNA knockdown. FGF2 siRNA transfection before the surgical injury inhibited activation of FGF2 and the injury-dependent expression of Snai1 and Zeb1 in the mouse corneal endothelium in vivo (Figure 4A). Moreover, FGF2 knockdown inhibited injury-dependent activation of Colla1, Colla2, Fn1, and Vim, and reversed the injury-dependent inhibition of Cdh1 (Figure 4B). Interestingly, the surgical injury also induced expression of Cdk2 and Ccen1, and this was inhibited by FGF2 knockdown in the mouse corneal endothelium in vivo (Figure 4C). These effects were not observed with non-targeting siRNA transfection, and keratocan (Ktcn), a corneal epithelial and stromal marker [42], was used to control for stromal and epithelial cell contamination (Figure 4D).
were no changes in the expression of Col8a2 and Actb in response to the injury or siRNA transfection. These results suggest that injury-induced endothelial to mesenchymal transition proceeds through FGF2 in the mouse corneal endothelium in vivo. 

**Inhibition of FGF2 signaling blocks the RCM formation induced by surgical injury in the mouse corneal endothelium in vivo:** We then investigated the role of FGF2 in RCM formation in the mouse corneal endothelium in vivo by performing surgical injury with or without FGF2 siRNA knockdown. Hematoxylin and eosin staining of the cornea 14 weeks after the surgical injury showed a multilayered and disorganized Descemet’s membrane in the absence of FGF2 siRNA knockdown (Figure 5B). Blocking of FGF2 signaling with siRNA knockdown inhibited the RCM formation induced by the surgical injury (Figure 5C). Interestingly, a

---

**Figure 2.** FGF2 regulates endothelial to mesenchymal transition–related gene expression in a time-dependent manner in mouse corneal endothelium ex vivo. Fifteen ex vivo corneas from nonobese diabetic (NOD; A, B, C, and D) and C57BL/6 (E, F, and G) mice were cultured for the indicated times (0, 1, 2, 3, or 7 days) with fibroblast growth factor 2 (FGF2). The endothelium–Descemet’s membrane complex was isolated, and total RNA was purified for reverse transcriptase PCR (RT–PCR). A: Increased expression of Snai1 and Zeb1 was noted in the FGF2-treated mouse corneal endothelium ex vivo as early as 2 days post-treatment. B: The FGF2 treatment led to increased expression of Col1a1, Col1a2, fibronectin (Fn1), and vimentin (Vim), and suppression of E-cadherin (Cdh1) in a time-dependent manner in the mouse corneal endothelium ex vivo. C: Increased expression of Cdk2 and Cyclin E1 (Ccne1) was noted in the FGF2-treated but not in the control mouse corneal endothelium ex vivo. D: The expression of Col8a2, a corneal endothelial marker, and β-actin (Actb), loading control, was not affected by FGF2. The data shown are representative of the results in three independent experiments. Veh C, vehicle control.

determine whether there were any strain differences in the FGF2 response. After being cultured for 7 days with FGF2, total RNA from mouse corneal endothelium ex vivo was purified, and RT–PCR was performed. E: Marked induction of the endothelial to mesenchymal transition markers Snai1 and Zeb1 was observed in the FGF2-treated but not in the vehicle control (Veh C) mouse corneal endothelium ex vivo. F: FGF2 treatment led to increased expression of Col1a1, Col1a2, fibronectin (Fn1), and vimentin (Vim), and suppression of E-cadherin (Cdh1) in the mouse ex vivo corneal endothelium. G: Increased expression of Cdk2 and Cyclin E1 (Ccne1) was noted in the FGF2-treated but not in the control mouse corneal endothelium ex vivo. Col8a2 and β-actin (Actb) expression was not affected by FGF2. The data shown are representative of the results in three independent experiments. Veh C, vehicle control.
Figure 3. IL-1β regulates endothelial to mesenchymal transition-related gene expression through FGF2 in the mouse corneal endothelium ex vivo. The mouse corneal endothelium ex vivo was transfected with either fibroblast growth factor 2 (FGF2) siRNA or non-targeting control siRNA (NT) and then maintained in organ culture with interleukin-1 beta (IL-1β) or vehicle control (Veh C). Total RNA was isolated at 14 days post-transfection. A: Induction of FGF2 with IL-1β stimulation was knocked down by FGF2 siRNA at up to 14 days post-transfection. RT–PCR showed inhibition of IL-1β-dependent expression of Snai1 and Zeb1 by FGF2 siRNA but not with non-targeting (NT) control siRNA. FGF2 one-way ANOVA, \(F(4,10)=43.4, p=0.002, n=3\) per sample. Tukey’s post-hoc test, honestly significant difference (HSD)[0.05]=1.6 and HSD[0.01]=2.1. Snai1 one-way ANOVA, \(F(4,10)=208.8, p<0.0001, n=3\) per sample. Tukey’s post-hoc test, HSD[0.05]=1.1 and HSD[0.01]=1.5. Zeb1 one-way ANOVA, \(F(4,10)=182.8, p<0.0001, n=3\) per sample. Tukey’s post-hoc test, HSD[0.05]=1.6 and HSD[0.01]=2.1. B: IL-1β-dependent expression of Col1a1, Col1a2, fibronectin (Fn1), and vimentin (Vim) was also inhibited by FGF2 siRNA but not non-targeting (NT) control siRNA. Col1a1 one-way ANOVA, \(F(4,10)=68.0, p=0.001, n=3\) per sample. Tukey’s post-hoc test, HSD[0.05]=2.3 and HSD[0.01]=3.1. Col1a2 one-way ANOVA, \(F(4,10)=759.0, p<0.0001, n=3\) per sample. Tukey’s post-hoc test, HSD[0.05]=1.0 and HSD[0.01]=1.3. Fn1 one-way ANOVA, \(F(4,10)=186.7, p<0.0001, n=3\) per sample. Tukey’s post-hoc test, HSD[0.05]=0.1 and HSD[0.01]=1.3. Vim one-way ANOVA, \(F(4,10)=122.0, p=0.001, n=3\) per sample. Tukey’s post-hoc test, HSD[0.05]=0.14 and HSD[0.01]=0.19. C: FGF2 siRNA also knocked down IL-1β-dependent expression of Cdk2 and Ccne1. Cdk2 one-way ANOVA, \(F(4,10)=152.9, p=0.001, n=3\) per sample. Tukey’s post-hoc test, HSD[0.05]=1.0 and HSD[0.01]=1.3. Ccne1 one-way ANOVA, \(F(4,10)=104.8, p=0.0003, n=3\) per sample. Tukey’s post-hoc test, HSD[0.05]=1.4 and HSD[0.01]=1.8. D) Expression of Col8a2 and β-actin (Actb) was not affected by siRNA. The data are representative of the results in three experiments. NT, non-targeting control; Veh C, vehicle control. * \(p<0.05\).
Figure 4. Surgical injury induces fibrosis- and proliferation-related genes through FGF2 in the mouse corneal endothelium in vivo. A: Surgical injury induced FGF2 and endothelial to mesenchymal transition markers Snai1 and Zeb1 in the mouse corneal endothelium in vivo. This could be inhibited by fibroblast growth factor 2 (FGF2) knockdown using FGF2 siRNA. Non-targeting siRNA (NT) had no effect on injury-induced gene expression. The uninjured control corneal endothelium showed no expression of Snai1 and Zeb1. FGF2 one-way ANOVA, F(3,8)=127.7, p=0.001, n=3 per sample. Tukey’s post-hoc test, honestly significant difference (HSD)[0.05]=1.4 and HSD[0.01]=2.0. Snai1 one-way ANOVA, F(3,8)=18.0, p=0.01, n=3 per sample. Tukey’s post-hoc test, HSD[0.05]=1.6 and HSD[0.01]=2.2. Zeb1 one-way ANOVA, F(3,8)=25.4, p=0.01, n=3 per sample. Tukey’s post-hoc test, HSD[0.05]=3.0 and HSD[0.01]=4.2. B: Surgical injury induced expression of Col1a1, Col1a2, Fn1, and Vim, and decreased expression of Cdh1 in the mouse corneal endothelium in vivo. This could be inhibited by FGF2 knockdown using FGF2 siRNA. Non-targeting siRNA (NT) had no effect on injury-induced gene expression. The uninjured control corneal endothelium showed no expression of Col1a1, Col1a2, Fn1, and Vim, and showed robust expression of Cdh1. Col1a1 one-way ANOVA, F(3,8)=16.3, p=0.02, n=3 per sample. Tukey’s post-hoc test, HSD[0.05]=3.5 and HSD[0.01]=4.8. Col1a2 one-way ANOVA, F(3,8)=54.9, p=0.005, n=3 per sample. Tukey’s post-hoc test, HSD[0.05]=2.6 and HSD[0.01]=3.6. Fn1 one-way ANOVA, F(3,8)=14.9, p=0.03, n=3 per sample. Tukey’s post-hoc test, HSD[0.05]=4.6 and HSD[0.01]=6.4. Vim one-way ANOVA, F(3,8)=77.8, p=0.003, n=3 per sample. Tukey’s post-hoc test, HSD[0.05]=2.3 and HSD[0.01]=3.2. Cdh1 one-way ANOVA, F(3,8)=359.2, p=0.0001, n=3 per sample. Tukey’s post-hoc test, HSD[0.05]=0.080 and HSD[0.01]=0.12. C: Surgical injury-induced expression of Cdk2 and Ccne1 in the mouse corneal endothelium in vivo. This could be inhibited by FGF2 knockdown using FGF2 siRNA. Non-targeting siRNA (NT) had no effect on injury-induced gene expression. The uninjured control corneal endothelium showed no expression of Cdk2 and Ccne1. Cdk2 one-way ANOVA, F(3,8)=102.3, p=0.002, n=3 per sample. Tukey’s post-hoc test, HSD[0.05]=1.7 and HSD[0.01]=2.4. Ccne1 one-way ANOVA, F(3,8)=21.7, p=0.02, n=3 per sample. Tukey’s post-hoc test, HSD[0.05]=2.9 and HSD[0.01]=4.0. D) Keratocan (Ktcn) was used as the control for contamination of the stromal keratocytes. Col8a2 and β-actin (Actb) were used as the corneal endothelial cell (CEC) marker and the loading control, respectively. The data shown are representative of the results in three independent experiments. C, Non-injured normal corneal endothelium; NT, non-targeting control. * p<0.05.
defect in Descemet’s membrane and the endothelium was still present at 14 weeks post injury. In the uninjured control, the cornea showed a well-organized monolayer of normal corneal endothelial cells (Figure 5A).

**DISCUSSION**

Endothelial to mesenchymal transition in the corneal endothelium can lead to RCM formation that often results in irreversible vision loss due to the progressive and fibrotic nature of RCM [43,44]. Although RCM formation is undesirable, endothelial to mesenchymal transition in the corneal endothelium could be exploited therapeutically for vision loss due to endothelial dysfunction if the individual components, i.e., migration, fibrosis, and proliferation, can be regulated independently of one another. Current challenges in investigating endothelial-mesenchymal transition in the human cornea include the environment-dependent behavior of CECs, e.g., markers or signals critical in vitro are not active in vivo, and the lack of a suitable model for human corneal endothelial behavior in vivo. In this study, we attempted to address the latter problem, and present evidence that the mouse corneal endothelium in vivo behaves in a similar manner to the human corneal endothelium ex vivo in response to injury.

IL-1β is a major proinflammatory cytokine in the human eye [45-47]. Previous studies have reported that IL-1β mediates the inflammatory process by inducing the production and release of secondary cytokines which are necessary for the wound repair process in a variety of cell types [12,13]. In human CECs in vitro, IL-1β has been shown to induce secretion of the 18-kDa isoform of FGF2 through AP-1 and nuclear factor kappa beta (NF-kB) [17-19]. Much like in the human corneal endothelium, we observed sequential secretion of IL-1β (Figure 1B) and FGF2 (Figure 1C) into the aqueous humor following surgical injury of the mouse corneal endothelium in vivo. Moreover, the thickening and disorganization of Descemet’s membrane following surgical injury (Figure 1A) is highly suggestive of early retrocorneal membrane formation in the mouse corneal endothelium in vivo. This demonstrates similarities in the early phase of endothelial to mesenchymal transition among human, rabbit, and mouse corneal endothelia [37,48].

FGF2 has previously been shown to be an initiator of endothelial to mesenchymal transition in the corneal endothelium in multiple species, including humans [49-51]. Our previous report showed that FGF2 induces expression of SNAI1, an endothelial to mesenchymal transition marker, which, in turn, activates expression of ZEB1 and Cdk2/Cyclin E1 (CCNE1). ZEB1 further induces endothelial to mesenchymal transition through suppression of E-cadherin and activation of type I collagen, fibronectin, and vimentin expression in the human corneal endothelium ex vivo [36]. Much like in the human corneal endothelium ex vivo, IL-1β
and FGF2 induced expression of *Snai1* and *Zeb1* in the mouse corneal endothelium ex vivo in a time-dependent manner (Figure 2 and Figure 3). Concomitant with the increased expression of *Snai1* and *Zeb1*, there also were increases in the expression of *Colla1*, *Colla2*, *Vim*, *Fnl*, *Cdk2*, and *Ccne1*, along with a decrease in *Cdhl* expression. Moreover, the IL-1β-mediated endothelial to mesenchymal transition could be abrogated with FGF2 siRNA knockdown, indicating FGF2 acts downstream of IL-1β in the mouse corneal endothelium ex vivo. This strongly suggests that the mouse corneal endothelium ex vivo and the human corneal endothelium ex vivo behave in a similar manner. There also does not appear to be any differences in the FGF2 response between the NOD and C57BL/6 strains of mice (Figure 2). Surgical injury induced expression of FGF2 (Figure 1), and this is followed by increased expression of *Colla1*, *Colla2*, *Vim*, *Fnl*, *Cdk2*, and *Ccne1*, along with decreased expression of *Cdhl* in the mouse corneal endothelium in vivo (Figure 4). FGF2 siRNA knockdown attenuated surgery-induced endothelial to mesenchymal transition (Figure 4) and prevented injury-induced RCM formation (Figure 5) in the mouse corneal endothelium in vivo. Moreover, the persistent endothelial and Descemet’s membrane defect 14 weeks after surgical injury (Figure 5C) indicates that FGF2 is critical for wound closure following surgical injury and plays a central role in EndoMT. The present data strongly suggest that regulation of endothelial to mesenchymal transition is very similar between the human corneal endothelium ex vivo and the mouse corneal endothelium in vivo, and support the use of the mouse as an

---

![Figure 6. Regulation of the endothelial to mesenchymal transition in the mouse corneal endothelium in vivo. Interleukin-1 beta (IL-1β) induced by surgical injury activates FGF2 expression. The endothelial to mesenchymal transition is mediated through Snail1, Zeb1 and Cdk2 pathways, leading to the expression of fibrosis- and proliferation-related genes resulting in the formation of the retrocorneal membrane (RCM).](image)
in vivo model for investigating regulation of endothelial to mesenchymal transition.

Previous studies focused on the prevention of RCM due to its progressive nature. However, modulation of individual components of endothelial to mesenchymal transition, that is, cell proliferation, migration, and fibrosis, may hold the key to developing novel therapeutic strategies for management of vision loss due to endothelial dysfunction. Although endothelial to mesenchymal transition involves a progressive change in cellular phenotype, cell proliferation, migration and fibrosis represent distinct phenotypes that could be under separate regulatory control. Our data in the human corneal endothelium ex vivo support this [36], and future therapies for vision loss could focus on promoting cell proliferation while simultaneously inhibiting fibrosis. Zeb1 is an attractive candidate for investigation because it acts downstream of FGF2, and its inhibition led to decreased expression of Col1a2 and Colla2 in the mouse corneal endothelium in vivo. In summary, induction of FGF2 through IL-1β in damaged corneal endothelium leads to increased expression of Snail and Zeb1. This then leads to increased expression of Vim and Fn1 along with fibrosis-related genes Col1a2 and Colla2, and proliferation-related genes Cdk2 and Ccn1 ultimately resulting in formation of a retrocorneal membrane (Figure 6).

ACKNOWLEDGMENTS
This study was supported by NIH P30EY029220 and an Unrestricted Departmental Grant from Research to Prevent Blindness. MH is a previous recipient of a Career Development Award from Research to Prevent Blindness.

REFERENCES
1. Joyce NC, Navon SE, Roy S, Zieske JD. Expression of cell cycle-associated proteins in human and rabbit corneal endothelium in situ. Invest Ophthalmol Vis Sci 1996; 37:1566-75. [PMID: 8675399].
2. Senoo T, Joyce NC. Cell cycle kinetics in corneal endothelium from old and young donors. Invest Ophthalmol Vis Sci 2000; 41:660-7. [PMID: 10711678].
3. Jakobic FA, Bhat P. Retrocorneal membranes: a comparative immunohistochemical analysis of keratocytic, endothelial, and epithelial origins. Am J Ophthalmol 2010; 150:230-42.
4. Rodrigues MM, Waring GO, Laibson PR, Weinreb S. Endothelial alterations in congenital corneal dystrophies. Am J Ophthalmol 1975; 80:678-89. [PMID: 1080955].
5. Waring GO 3rd. Posterior collagenous layer of the cornea. Ultrastructural classification of abnormal collagenous tissue posterior to Descemet's membrane in 30 cases. Arch Ophthalmol 1982; 100:122-34. [PMID: 7055463].
6. Song JS, Lee JG, Kay EP. Induction of FGF-2 synthesis by IL-1β in aqueous humor through P13-kinase and p38 in rabbit corneal endothelium. Invest Ophthalmol Vis Sci 2010; 51:822-9. [PMID: 19797202].
7. Kay EP, Smith RE, Ninomiya Y, Smith RE. Corneal endothelial modulation: a factor released by leukocytes induces basic fibroblast growth factor that modulates cell shape and collagen. Invest Ophthalmol Vis Sci 1993; 34:663-72. [PMID: 8449685].
8. Djallian AR, Nagineni CN, Mahesh SP, Smith JA, Nussenblatt RB, Hooks JJ. Inhibition of inflammatory cytokine production in human corneal cells by dexamethasone, but not cyclosporin. Cornea 2006; 25:709-14. [PMID: 17077666].
9. Moore JE, McMullen TC, Campbell IL, Rohan R, Kaji Y, Afshari NA, Usui T, Archer DB, Adams AP. The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy. Invest Ophthalmol Vis Sci 2002; 43:2905-15. [PMID: 12202509].
10. McDermott AM, Redfern RL, Zhang B, Pei Y, Huang L, Proske RJ. Defensin expression by the cornea: multiple signalling pathways mediate IL-1β stimulation of hBD-2 expression by human corneal epithelial cells. Invest Ophthalmol Vis Sci 2003; 44:1859-65. [PMID: 12714616].
11. Jung YD, Liu W, Reimnuth N, Ahmad SA, Fan F, Gallick GE, Ellis LM. Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway. Angiogenesis 2001; 4:155-62. [PMID: 11806247].
12. Pshenichkin SP, Szekely AM, Wise BC. Transcriptional and posttranscriptional mechanisms involved in the interleukin-1, steroid, and protein kinase C regulation of nerve growth factor in cortical astrocytes. J Neurochem 1994; 63:419-28. [PMID: 8035171].
13. Cronauer MV, Stadtmann S, Klocker H, Abendstein B, Eder IE, Rogatsch H, Zeimet AG, Marth C, Offner FA. Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1. Am J Pathol 1999; 155:1977-84. [PMID: 10599927].
14. Sobue T, Zhang X, Florkiewicz RZ, Hurley MM. Interleukin-1 regulates FGF-2 mRNA and localization of FGF-2 protein in human osteoblasts. Biochem Biophys Res Commun 2001; 286:33-40. [PMID: 11485304].
15. Hayashi T, Matsuoka K, Saiot M, Takeda S, Kimura M. Influence of alpha-tumor necrosis factor and beta-interleukin-1 on production of angiogenic factors and thymidine phosphorylase activity in immortalized human decidual fibroblasts in vitro. J Obstet Gynaecol Res 2006; 32:15-22. [PMID: 16445521].
16. Lee JG, Heur M. Interleukin-1beta enhances cell migration through AP-1 and NF-kappaB pathway-dependent FGF2
expression in human corneal endothelial cells. Biol Cell 2013; 105:175-89. [PMID: 23331079].

18. Lee JG, Kay EP. NF-kappaB is the transcription factor for FGF-2 that causes endothelial mesenchymal transformation in cornea. Invest Ophthalmol Vis Sci 2012; 53:1530-8. [PMID: 22323467].

19. Lee JG, Kay EP. Common and distinct pathways for cellular activities in FGF-2 signaling induced by IL-1beta in corneal endothelial cells. Invest Ophthalmol Vis Sci 2009; 50:2067-76. [PMID: 19136710].

20. Klint P, Claesson-Welsh L. Signal transduction by fibroblast growth factor receptors. Front Biosci 1999; 4:D165-77. [PMID: 9989949].

21. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16:139-49. [PMID: 15860303].

22. Frinchi M, Bonomo A, Trovato-Salinaro A, Condorelli DF, Fuxe K, Spampinato MG, Mudo G. Fibroblast growth factor-2 and its receptor expression in proliferating precursor cells of the subventricular zone in the adult rat brain. Neurosci Lett 2008; 447:20-5. [PMID: 18835325].

23. Lee JG, Kay EP. Two populations of p27 use differential kinetics to phosphorylate Ser-10 and Thr-187 via phosphatidylinositol 3-Kinase in response to fibroblast growth factor stimulation. J Biol Chem 2007; 282:6444-54. [PMID: 17209046].

24. Lee JG, Kay EP. Involvement of two distinct ubiquitin E3 ligase systems for p27 degradation in corneal endothelial cells. Invest Ophthalmol Vis Sci 2008; 49:189-96. [PMID: 18172092].

25. Lee JG, Kay EP. FGF-2-induced wound healing in corneal endothelial cells requires Cdc42 activation and Rho inactivation through the phosphatidylinositol 3-kinase pathway. Invest Ophthalmol Vis Sci 2006; 47:1376-86. [PMID: 16565371].

26. Ko MK, Kay EP. Regulatory role of FGF-2 on type I collagen expression during endothelial mesenchymal transformation. Invest Ophthalmol Vis Sci 2005; 46:4495-503. [PMID: 16303940].

27. Lee JG, Kay EP. Cross-talk among Rho GTPases acting downstream of PI 3-kinase induces mesenchymal transformation of corneal endothelial cells mediated by FGF-2. Invest Ophthalmol Vis Sci 2006; 47:2358-68. [PMID: 16723445].

28. Thiery JP, Acolque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139:871-90. [PMID: 19945376].

29. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119:1420-8. [PMID: 19487818].

30. Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol 2003; 19:207-35. [PMID: 14570569].

31. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000; 2:84-9. [PMID: 10655587].

32. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7:415-28. [PMID: 17508028].

33. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2:76-83. [PMID: 10655586].

34. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009; 119:1429-37. [PMID: 19487819].

35. Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol 2011; 179:1074-80. [PMID: 21763673].

36. Lee JG, Jung E, Heur M. Fibroblast growth factor 2 induces proliferation and fibrosis via SNAIL-mediated activation of CDK2 and ZEB1 in corneal endothelium. J Biol Chem 2018; 293:3758-69. [PMID: 29363574].

37. Kay ED, Cheung CC, Jester JV, Nimni ME, Smith RE. Type I collagen and fibronectin synthesis by retrocorneal fibrous membrane. Invest Ophthalmol Vis Sci 1982; 22:200-12. [PMID: 7035994].

38. Okumura N, Kay EP, Nakahara M, Hamujo J, Kinoshita S, Koizumi N. Inhibition of TGF-beta signaling enables human corneal endothelial cell expansion in vitro for use in regenerative medicine. PLoS One 2013; 8:e58000-[PMID: 23451286].

39. Lee JG, Heur M. WNT10B enhances proliferation through beta-catenin and RAC1 GTPase in human corneal endothelial cells. J Biol Chem 2015; 290:26752-64. [PMID: 26370090].

40. Lee HT, Lee JG, Na M, Kay EP. FGF-2 induced by interleukin-1 beta through the action of phosphatidylinositol 3-kinase mediates endothelial mesenchymal transformation in corneal endothelial cells. J Biol Chem 2004; 279:32325-32. [PMID: 15173165].

41. Choi J, Ko MK, Kay EP. Subcellular localization of the expressed 18 kDa FGF-2 isoform in corneal endothelial cells. Mol Vis 2000; 6:222-31. [PMID: 11073556].

42. Zulkafli MA, Stock EL, Jones JC. Expression of the 55-kD/64-kD corneal keratins in ocular surface epithelium. Invest Ophthalmol Vis Sci 1990; 31:448-56. [PMID: 1690687].

43. Kremer I, Rapuano CJ, Cohen EJ, Laibson PR, Eagle RC Jr. Retrocorneal fibrous membranes in failed corneal grafts. Am J Ophthalmol 1993; 115:478-83. [PMID: 8470720].

44. Kremer I, Zandbank J, Barash D, Ben-David E, Yassur Y. Extensive fibrous downgrowth after traumatic corneoscleral wound dehiscence. Ann Ophthalmol 1991; 23:465-8. [PMID: 1785905].

45. Karthikeyan RS, Leal SM Jr, Prajna NV, Dharmalingam K, Geiser DM, Pearlman E, Lalitha P. Expression of innate and...
Adaptive immune mediators in human corneal tissue infected with Aspergillus or fusarium. J Infect Dis 2011; 204:942-50. [PMID: 21828275].

46. Erdinest N, Shmueli O, Grossman Y, Ovadia H, Solomon A. Anti-inflammatory effects of alpha linolenic acid on human corneal epithelial cells. Invest Ophthalmol Vis Sci 2012; 53:4396-406. [PMID: 22669722].

47. Kruger T, Cao Y, Kjaergaard SK, Knudsen LE, Bonefeld-Jorgensen EC. Effects of phthalates on the human corneal endothelial cell line B4G12. Int J Toxicol 2012; 31:364-71. [PMID: 22723514].

48. Michels RG, Kenyon KR, Maumence AE. Retrocorneal fibrous membrane. Invest Ophthalmol 1972; 11:822-31. [PMID: 4116098].

49. Zhu YT, Chen HC, Chen SY, Tseng SC. Nuclear p120 catenin unlocks mitotic block of contact-inhibited human corneal endothelial monolayers without disrupting adherent junctions. J Cell Sci 2012; 125:3636-48. [PMID: 22505615].

50. Lee JG, Ko MK, Kay EP. Endothelial mesenchymal transformation mediated by IL-1beta-induced FGF-2 in corneal endothelial cells. Exp Eye Res 2012; 95:35-9. [PMID: 21855543].

51. Roy O, Leclerc VB, Bourget JM, Theriault M, Proulx S. Understanding the process of corneal endothelial morphological change in vitro. Invest Ophthalmol Vis Sci 2015; 56:1228-37. [PMID: 25698769].